Last reviewed · How we verify
Verve Medical, Inc — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abbott · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 shared drug class
- EMS · 1 shared drug class
- Kaohsiung Medical University Chung-Ho Memorial Hospital · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Verve Medical, Inc:
- Verve Medical, Inc pipeline updates — RSS
- Verve Medical, Inc pipeline updates — Atom
- Verve Medical, Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Verve Medical, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/verve-medical-inc. Accessed 2026-05-16.